Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.

ABSTRACT: Tuberculosis (TB) continues to be a major infectious disease affecting individuals worldwide. Current TB treatment strategy recommends the standard short-course chemotherapy regimen containing first-line drug, i.e., isoniazid, rifampicin, pyrazinamide, and ethambutol to treat patients suffering from drug-susceptible TB. Although Mycobacterium tuberculosis , the causing agent, is susceptible to drugs, some patients do not respond to the treatment or treatment may result in serious adverse reactions. Many studies revealed that anti-TB drug-related toxicity is associated with genetic variations, and these variations may also influence attaining maximum drug concentration. Thus, inter-individual diversities play a characteristic role by influencing the genes involved in drug metabolism

SUBMITTER: Khan A 

PROVIDER: S-EPMC9192167 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature